Author

Shaoying Li

UT MD Anderson Cancer Center - Cited by 6,631 - lymphoma - leukemia - myeloma

Biography

Shaoying Li is a well-known researcher working in Department of Hematopathology, Division of Pathology-Lab Medicine and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
Additive manufacturing of polymeric composites from material processing to structural design
S Yuan, S Li, J Zhu, Y TangComposites Part B: Engineering 219, 108903, 2021202
100
2021
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
ML Wang, P Jain, S Zhao, HJ Lee, L Nastoupil, L Fayad, CY Ok, ...The Lancet Oncology 23 (3), 406-415, 2022202
19
2022
Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm
CC Yin, N Pemmaraju, MJ You, S Li, J Xu, W Wang, Z Tang, O Alswailmi, ...Cancers (23), 5888, 2021202
13
2021
Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge
M Khanlari, LJ Medeiros, P Lin, J Xu, MJ You, G Tang, CC Yin, W Wang, ...Modern Pathology 35 (3), 419-426, 2022202
11
2022
Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases
H Fang, SA Wang, JD Khoury, S El Hussein, DH Kim, M Tashakori, ...Haematologica 7 (9), 2232, 2022202
10
2022
Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal–regulated …
S Garces, LJ Medeiros, ML Marques-Piubelli, SAC Siqueira, RN Miranda, ...Human Pathology 121, 36-45, 2022202
10
2022
Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-hypercvad/MTX in young patients with previously untreated mantle cell …
M Wang, P Jain, HJ Lee, CY Ok, H Hill, L Navsaria, R Kanagal-Shamanna, ...Blood 138, 3525, 2021202
7
2021
DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
L Qiu, G Tang, S Li, F Vega, P Lin, SA Wang, W Wang, SP Iyer, L Malpica, ...Haematologica 108 (), 104, 2023202
6
2023
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients …
A Augustyn, LJ Medeiros, EB Ludmir, J Gunther, P Fang, S Li, CY Ok, ...Leukemia & lymphoma 62 (6), 1361-1369, 2021202
5
2021
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience
S Konoplev, X Wang, G Tang, S Li, W Wang, J Xu, SA Pierce, F Jia, ...Cytometry Part B: Clinical Cytometry 102 (2), 123-133, 2022202
5
2022
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
D Martinez-Baquero, A Sakhdari, H Mo, DH Kim, R Kanagal-Shamanna, ...Modern Pathology 4 (12), 218-2191, 2021202
3
2021
Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall
L Qiu, J Xu, G Tang, SA Wang, P Lin, CY Ok, S Garces, CC Yin, ...Human Pathology 119, 59-68, 2022202
3
2022
High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS): characteristics, treatment, and outcomes from 17 academic US centers
A Zayac, DJ Landsburg, M Hughes, EC Ayers, M Girton, M Hu, ...Blood 18 (Supplement 1), 455-455, 2021202
3
2021
Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ …
M Khanlari, S Li, RN Miranda, S Iyer, S Konoplev, P Lin, CC Yin, G Tang, ...Modern Pathology 5 (), 412-418, 2022202
3
2022
Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma
L Qiu, J Xu, P Lin, EN Cohen, G Tang, SA Wang, M Khanlari, W Wang, ...Haematologica 108 (), 895, 20220
3
2023
PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
W Xie, LJ Medeiros, S Li, G Tang, G Fan, J XuBiomedicines 10 (7), 1587, 0
2
2022
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
N Epperla, A Zayac, DJ Landsburg, M Hughes, AM Bock, GS Nowakowski, ...Blood 140 (Supplement 1), 3839-3841, 0
2
2022
MUM1/IRF4 is highly expressed in dermatopathic lymphadenopathy: potential utility in diagnosis and differential diagnosis
S Garces, Z Rudzki, CC Yin, RN Miranda, AM Medina, V Sriganeshan, ...The American Journal of Surgical Pathology 46 (11), 1514-153, 0
2
2022
The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation
Y Wang, AE Quesada, Z Zuo, LJ Medeiros, CC Yin, S Li, J Xu, ...Cancers 15 (1), 198, 0
2
2022
High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL
S Li, L Qiu, J Xu, P Lin, CY Ok, G Tang, TJ McDonnell, M James You, ...Leukemia 37 (2), 422-432, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=LVB6k8EAAAAJ&hl=en

Cited by
Citations 6631
h-index 42
i10-index 103
Recommended Journals
Open Access Journals